Trial Profile
A Randomized Study of 4 vs. 8 Cycles of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients.
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 20 Sep 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 06 Dec 2012 Planned end date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 02 Oct 2009 New trial record